Two Sigma Securities’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,900
Closed -$374K 1951
2024
Q3
$374K Hold
1,900
0.01% 1559
2024
Q2
$393K Sell
1,900
-1,500
-44% -$340K ﹤0.01% 1750
2024
Q1
$921K Buy
3,400
+400
+13% +$95.5K 0.01% 1186
2023
Q4
$709K Buy
3,000
+1,300
+76% +$256K 0.01% 1288
2023
Q3
$333K Buy
1,700
+300
+21% +$61.6K ﹤0.01% 1863
2023
Q2
$294K Sell
1,400
-700
-33% -$139K ﹤0.01% 1900
2023
Q1
$424K Sell
2,100
-600
-22% -$136K 0.01% 1390
2022
Q4
$588K Sell
2,700
-200
-7% -$43.7K 0.02% 977
2022
Q3
$571K Buy
+2,900
New +$626K 0.02% 989
2020
Q1
Sell
-5,700
Closed -$871K 1503
2019
Q4
$871K Buy
+5,700
New +$789K 0.01% 1117
2019
Q3
Sell
-2,200
Closed -$312K 2107
2019
Q2
$312K Buy
2,200
+500
+29% +$67.8K ﹤0.01% 1428
2019
Q1
$247K Buy
+1,700
New +$223K ﹤0.01% 1317
2018
Q4
Sell
-4,500
Closed -$605K 2249
2018
Q3
$605K Sell
4,500
-5,500
-55% -$679K ﹤0.01% 1301
2018
Q2
$1.12M Buy
+10,000
New +$1.08M 0.01% 1266

Other funds holding CRL

Two Sigma Securities's CRL Position: Q3 2025 in Review

Two Sigma Securities sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 4,996 shares — an estimated $758K sold.

Two Sigma Securities first reported a position in CRL in Q4 2018 and held it in 10 quarters. The position peaked at $758K in Q2 2025. 556 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • Two Sigma Securities reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 4,996 Charles River Laboratories shares in Q3 2025, an estimated $758K.
  • Two Sigma Securities first reported a position in Charles River Laboratories in Q4 2018 and held it in 10 quarters.
  • Two Sigma Securities's Charles River Laboratories position peaked at $758K in Q2 2025.
  • 556 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.